BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ziske C, Schlie C, Gorschlüter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, Schmidt-Wolf IG. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89:1413-7. [PMID: 14562009 DOI: 10.1038/sj.bjc.6601263] [Cited by in Crossref: 114] [Cited by in F6Publishing: 112] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15-22. [PMID: 22729569 DOI: 10.1002/jso.23192] [Cited by in Crossref: 137] [Cited by in F6Publishing: 141] [Article Influence: 13.7] [Reference Citation Analysis]
2 Ali CW, Kaye TF, Adamson DJ, Tait IS, Polignano FM, Highley MS. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma. J Gastrointest Cancer. 2007;38:108-114. [PMID: 19089662 DOI: 10.1007/s12029-008-9019-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
3 Okada K, Kawai M, Tani M, Hirono S, Miyazawa M, Shimizu A, Kitahata Y, Yamaue H. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:648-53. [DOI: 10.1002/jhbp.109] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
4 Wasan HS, Springett GM, Chodkiewicz C, Wong R, Maurel J, Barone C, Rosbrook B, Ricart AD, Kim S, Spano JP. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer 2009;101:1162-7. [PMID: 19724276 DOI: 10.1038/sj.bjc.6605243] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
5 Passerini R, Riggio D, Salvatici M, Zorzino L, Radice D, Sandri MT. Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update. Clinical Chemical Laboratory Medicine 2007;45. [DOI: 10.1515/cclm.2007.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
6 Sawada M, Kasuga A, Mie T, Furukawa T, Taniguchi T, Fukuda K, Yamada Y, Takeda T, Kanata R, Matsuyama M, Sasaki T, Ozaka M, Sasahira N. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer 2020;20:449. [PMID: 32434547 DOI: 10.1186/s12885-020-06945-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
7 Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007;56:1134-1152. [PMID: 17625148 DOI: 10.1136/gut.2006.103333] [Cited by in Crossref: 84] [Cited by in F6Publishing: 179] [Article Influence: 5.6] [Reference Citation Analysis]
8 Curry JM, Thompson KJ, Rao SG, Besmer DM, Murphy AM, Grdzelishvili VZ, Ahrens WA, McKillop IH, Sindram D, Iannitti DA, Martinie JB, Mukherjee P. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J Surg Oncol 2013;107:713-22. [PMID: 23335066 DOI: 10.1002/jso.23316] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
9 Shibata K, Iwaki K, Kai S, Ohta M, Kitano S. Increased Levels of Both Carbohydrate Antigen 19-9 and Duke Pancreatic Monoclonal Antigen Type 2 Reflect Postoperative Prognosis in Patients With Pancreatic Carcinoma. Pancreas 2009;38:619-24. [DOI: 10.1097/mpa.0b013e3181a53ee7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
10 Sawaki A, Kanemitsu Y, Mizuno N, Takahashi K, Nakamura T, Ioka T, Tanaka S, Nakaizumi A, Salem AA, Ueda R, Yamao K. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol 2008;23:1292-7. [PMID: 18700899 DOI: 10.1111/j.1440-1746.2006.04734.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
11 Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008;37:269-274. [PMID: 18815548 DOI: 10.1097/mpa.0b013e31816d8185] [Cited by in Crossref: 62] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
12 Xu B, Zheng WY, Jin DY, Ding WX, Lou WH, Ramsohok L. Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. World J Surg. 2011;35:1103-1109. [PMID: 21416173 DOI: 10.1007/s00268-011-1003-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
13 Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M, Colomban O, You B. A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol 2014;25:41-56. [PMID: 24356619 DOI: 10.1093/annonc/mdt382] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
14 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021] [Cited by in F6Publishing: 220] [Reference Citation Analysis]
15 Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer. 2008;99:883-893. [PMID: 19238630 DOI: 10.1038/sj.bjc.6604568] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
16 Hines OJ, Reber HA. Pancreatic neoplasms. Curr Opin Gastroenterol. 2004;20:452-458. [PMID: 15689678 DOI: 10.1097/00001574-200409000-00006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
17 Morizane C, Okusaka T, Morita S, Tanaka K, Ueno H, Kondo S, Ikeda M, Nakachi K, Mitsunaga S. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas. 2011;40:415-421. [PMID: 21283041 DOI: 10.1097/mpa.0b013e3182021376] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
18 Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013; 19(28): 4511-4519 [PMID: 23901226 DOI: 10.3748/wjg.v19.i28.4511] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
19 Martin LK, Wei L, Trolli E, Bekaii-Saab T. Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Med Oncol. 2012;29:3101-3107. [PMID: 22729400 DOI: 10.1007/s12032-012-0278-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
20 Kuhlmann KF, van Till JW, Boermeester MA, de Reuver PR, Tzvetanova ID, Offerhaus GJ, Ten Kate FJ, Busch OR, van Gulik TM, Gouma DJ, Crawford HC. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16:886-91. [PMID: 17507610 DOI: 10.1158/1055-9965.EPI-06-0779] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
21 Ferreira JA, Peixoto A, Neves M, Gaiteiro C, Reis CA, Assaraf YG, Santos LL. Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resistance Updates 2016;24:34-54. [DOI: 10.1016/j.drup.2015.11.003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 13.3] [Reference Citation Analysis]
22 Temraz S, Shamseddine A, Mukherji D, Charafeddine M, Tfayli A, Assi H, Hammoud MS, Makki I, Nassif S. Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis. Pathol Oncol Res 2019;25:1059-66. [PMID: 30187215 DOI: 10.1007/s12253-018-0464-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Woo HI, Kim KK, Choi H, Kim S, Jang KT, Yi JH, Park YS, Park JO, Lee SY. Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. Pharmacogenomics 2012;13:1023-35. [PMID: 22838950 DOI: 10.2217/pgs.12.82] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
24 Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol. 2011;2:88-100. [PMID: 22693400 DOI: 10.1007/s13193-011-0042-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 11.1] [Reference Citation Analysis]
25 Tsutsumi K, Kawamoto H, Hirao K, Sakakihara I, Yamamoto N, Noma Y, Fujii M, Kato H, Ogawa T, Ishida E. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Pancreatology. 2012;12:409-416. [PMID: 23127528 DOI: 10.1016/j.pan.2012.07.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
26 Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005;93:195-9. [PMID: 15999098 DOI: 10.1038/sj.bjc.6602687] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 6.3] [Reference Citation Analysis]
27 Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K, Yano M. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 2010;251:461-9. [PMID: 20134315 DOI: 10.1097/SLA.0b013e3181cc90a3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
28 Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 2013;119:285-292. [PMID: 22786786 DOI: 10.1002/cncr.27734] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 7.0] [Reference Citation Analysis]
29 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(11): 2525-2526 [DOI: 10.11569/wcjd.v12.i11.2525] [Reference Citation Analysis]
30 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
31 Hernandez JM, Cowgill SM, Al-Saadi S, Collins A, Ross SB, Cooper J, Villadolid D, Zervos E, Rosemurgy A. CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg. 2009;13:349-353. [PMID: 18972170 DOI: 10.1007/s11605-008-0696-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
32 Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740-743. [PMID: 16175188 DOI: 10.1038/sj.bjc.6602760] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 5.8] [Reference Citation Analysis]
33 O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res. 2015;21:622-631. [PMID: 24938522 DOI: 10.1158/1078-0432.ccr-14-0365] [Cited by in Crossref: 101] [Cited by in F6Publishing: 65] [Article Influence: 12.6] [Reference Citation Analysis]
34 Colloca GA, Venturino A, Guarneri D. Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy: A retrospective analysis. Pancreatology 2020;20:1189-94. [PMID: 32747196 DOI: 10.1016/j.pan.2020.07.397] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Hammad N, Heilbrun LK, Philip PA, Shields AF, Zalupski MM, Venkatramanamoorthy R, El-Rayes BF. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia Pac J Clin Oncol. 2010;6:98-105. [PMID: 20565421 DOI: 10.1111/j.1743-7563.2010.01290.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
36 Grunnet M, Mau-Sørensen M. Serum tumor markers in bile duct cancer--a review.Biomarkers. 2014;19:437-443. [PMID: 24857368 DOI: 10.3109/1354750X.2014.923048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
37 Maréchal R, Demols A, Gay F, De Maertelaere V, Arvanitaki M, Hendlisz A, Van Laethem J. Prognostic Factors and Prognostic Index for Chemonaïve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer. Oncology 2007;73:41-51. [DOI: 10.1159/000120627] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
38 Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 wk as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016;27:654-660. [PMID: 26802160 DOI: 10.1093/annonc/mdw006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
39 Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC. ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. JCO 2006;24:5313-27. [DOI: 10.1200/jco.2006.08.2644] [Cited by in Crossref: 960] [Cited by in F6Publishing: 451] [Article Influence: 60.0] [Reference Citation Analysis]
40 Wong HCY, Lam KY, Chong CCN, Chan AWH, Chan SL. Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer. Nutr Cancer 2019;71:954-70. [PMID: 31058551 DOI: 10.1080/01635581.2019.1595047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
41 Awad S, Alkashash AM, Amin M, Baker SJ, Rose JB. Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:620. [PMID: 32477933 DOI: 10.3389/fonc.2020.00620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Xu Z, Zhang Y, Jiang J, Yang Y, Shi R, Hao B, Zhang Z, Huang Z, Kim JW, Zhang G. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells. BMC Cancer. 2010;10:161. [PMID: 20423485 DOI: 10.1186/1471-2407-10-161] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
43 Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441-447. [PMID: 19690057 DOI: 10.1093/annonc/mdp332] [Cited by in Crossref: 207] [Cited by in F6Publishing: 193] [Article Influence: 15.9] [Reference Citation Analysis]
44 Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008;72:678-686. [PMID: 18395362 DOI: 10.1016/j.ijrobp.2008.01.051] [Cited by in Crossref: 228] [Cited by in F6Publishing: 205] [Article Influence: 16.3] [Reference Citation Analysis]
45 Laurent L, Sefrioui D, Bignon AL, Parzy A, Sidali S, Hassine M, Gangloff A, Galais MP, Bouhier-Leporrier K, Michel P, Di Fiore F. CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. HPB (Oxford) 2019;21:582-8. [PMID: 30466797 DOI: 10.1016/j.hpb.2018.09.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Jiang K, Tan E, Sayegh Z, Centeno B, Malafa M, Coppola D. Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. Appl Immunohistochem Mol Morphol. 2016; Epub ahead of print. [PMID: 27093451 DOI: 10.1097/pai.0000000000000368] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
47 Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, Dumoulin FL. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 2006; 12(34): 5495-5500 [PMID: 17006987 DOI: 10.3748/wjg.v12.i34.5495] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
48 Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35:7459-7465. [PMID: 24789274 DOI: 10.1007/s13277-014-1995-9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
49 Grunnet M, Christensen IJ, Lassen U, Jensen LH, Lydolph M, Knox JJ, Mcnamara MG, Jitlal M, Wasan H, Bridgewater J, Valle JW, Mau-sorensen M. Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. European Journal of Cancer 2015;51:1381-8. [DOI: 10.1016/j.ejca.2015.04.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
50 Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol. 2006;24:252-258. [PMID: 16344318 DOI: 10.1200/jco.2005.02.8282] [Cited by in Crossref: 86] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
51 Terakawa N, Satoi S, Takai S, Yanagimoto H, Takahashi K, Komiyama Y, A-hon K, Kamiyama Y, Takahashi H. Clinical Monitoring of Innate Cellular Immunity of Monocytes/Macrophages by Tumor Necrosis Factor Alpha Productivity in Whole Blood Stimulated by Lipopolysaccharide in Patients with Pancreatic Cancer. Pancreas 2006;33:31-7. [DOI: 10.1097/01.mpa.0000226880.66130.79] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
52 Clayton AJ, Mansoor AW, Jones ET, Hawkins RE, Saunders MP, Swindell R, Valle JW. A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing? Pancreas 2006;32:51-7. [PMID: 16340744 DOI: 10.1097/01.mpa.0000188306.67420.0f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
53 Golan T, Khvalevsky EZ, Hubert A, Gabai RM, Hen N, Segal A, Domb A, Harari G, David EB, Raskin S, Goldes Y, Goldin E, Eliakim R, Lahav M, Kopleman Y, Dancour A, Shemi A, Galun E. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget. 2015;6:24560-24570. [PMID: 26009994 DOI: 10.18632/oncotarget.4183] [Cited by in Crossref: 139] [Cited by in F6Publishing: 134] [Article Influence: 23.2] [Reference Citation Analysis]
54 Bartosch-Härlid A, Andersson B, Aho U, Nilsson J, Andersson R. Artificial neural networks in pancreatic disease. Br J Surg. 2008;95:817-826. [PMID: 18551536 DOI: 10.1002/bjs.6239] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
55 Chen Y, Shao Z, Chen W, Xie H, Wu Z, Qin G, Zhao N. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer. Oncotarget 2017;8:29925-34. [PMID: 28404893 DOI: 10.18632/oncotarget.15557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
56 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.ssn.2078-6891.2011.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Gelibter A, Malaguti P, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Carboni F, Ettorre GM, Pellicciotta M, Giannarelli D, Terzoli E, Cognetti F, Milella M. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005;104:1237-45. [PMID: 16078261 DOI: 10.1002/cncr.21286] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
58 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.1002/ijc.20037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
59 Debernardi S, O'Brien H, Algahmdi AS, Malats N, Stewart GD, Plješa-Ercegovac M, Costello E, Greenhalf W, Saad A, Roberts R, Ney A, Pereira SP, Kocher HM, Duffy S, Blyuss O, Crnogorac-Jurcevic T. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. PLoS Med 2020;17:e1003489. [PMID: 33301466 DOI: 10.1371/journal.pmed.1003489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
60 Jiang JT, Wu CP, Deng HF, Lu MY, Wu J, Zhang HY, Sun WH, Ji M. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol 2004; 10(11): 1675-1677 [PMID: 15162550 DOI: 10.3748/wjg.v10.i11.1675] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
61 Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs 2019;37:473-81. [PMID: 30298303 DOI: 10.1007/s10637-018-0676-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
62 Zhang D, Hou W, Liu F, Yin J, Lu W, Li M, Zheng T, Lu F, Bao Y, Jia W. Metformin reduces serum CA199 levels in type 2 diabetes Chinese patients with time-effect and gender difference. Diabetes Technol Ther. 2015;17:72-79. [PMID: 25548963 DOI: 10.1089/dia.2014.0176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
63 Tas F, Sen F, Odabas H, Kılıc L, Keskın S, Yıldız I. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 2013;18:839-46. [PMID: 22996141 DOI: 10.1007/s10147-012-0474-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
64 Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, Goodman KA, Koong AC, Chang DT. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77:1420-1425. [PMID: 20056345 DOI: 10.1016/j.ijrobp.2009.06.049] [Cited by in Crossref: 97] [Cited by in F6Publishing: 79] [Article Influence: 8.1] [Reference Citation Analysis]
65 Martin LK, Li X, Kleiber B, Ellison EC, Bloomston M, Zalupski M, Bekaii-Saab TS. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Ann Oncol. 2012;23:2812-2820. [PMID: 22767582 DOI: 10.1093/annonc/mds134] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
66 Yamagishi Y, Higuchi H, Izumiya M, Sakai G, Iizuka H, Nakamura S, Adachi M, Hozawa S, Takaishi H, Hibi T. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol 2010;45:1146-54. [DOI: 10.1007/s00535-010-0258-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
67 Mitsunaga S, Kinoshita T, Hasebe T, Nakagohri T, Konishi M, Takahashi S, Gotohda N, Ochiai A. Low Serum Level of Cholinesterase at Recurrence of Pancreatic Cancer Is a Poor Prognostic Factor and Relates to Systemic Disorder and Nerve Plexus Invasion. Pancreas 2008;36:241-8. [DOI: 10.1097/mpa.0b013e31815b6b2b] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
68 Sutera PA, Bernard ME, Gill BS, Harper KK, Quan K, Bahary N, Burton SA, Zeh H, Heron DE. One- vs. Three-Fraction Pancreatic Stereotactic Body Radiation Therapy for Pancreatic Carcinoma: Single Institution Retrospective Review. Front Oncol 2017;7:272. [PMID: 29184848 DOI: 10.3389/fonc.2017.00272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
69 Colloca G, Venturino A, Guarneri D. CA19-9-related tumor kinetics after first-line chemotherapy of patients with advanced pancreatic cancer: a monoinstitutional experience. Med Oncol 2016;33:103. [PMID: 27522503 DOI: 10.1007/s12032-016-0817-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Robert M, Jarlier M, Gourgou S, Desseigne F, Ychou M, Bouché O, Juzyna B, Conroy T, Bennouna J. Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4). Oncology 2017;93:367-76. [DOI: 10.1159/000477850] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
71 Niwa T, Ueno M, Shinya N, Gotoh T, Kwee TC, Takahara T, Yoshida T, Ohkawa S, Doiuchi T, Inoue T. Dynamic susceptibility contrast MRI in advanced pancreatic cancer: semi-automated analysis to predict response to chemotherapy: DYNAMIC SUSCEPTIBILITY CONTRAST MRI IN ADVANCED PANCREATIC CANCER. NMR Biomed 2010;23:347-52. [DOI: 10.1002/nbm.1467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs. 2005;23:369-375. [PMID: 16012797 DOI: 10.1007/s10637-005-1446-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
73 Akisik MF, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology. 2010;256:441-449. [PMID: 20515976 DOI: 10.1148/radiol.10091733] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 6.4] [Reference Citation Analysis]
74 Choi SH, Park SW, Seong J. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiother Oncol 2018;129:340-6. [PMID: 30177371 DOI: 10.1016/j.radonc.2018.08.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
75 Chen Y, Wang YR, Deng GC, Dai GH. CA19-9 decrease and survival according to platelet level in patients with advanced pancreatic cancer.BMC Cancer. 2019;19:860. [PMID: 31470818 DOI: 10.1186/s12885-019-6078-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
76 Ishizone S, Yamauchi K, Kawa S, Suzuki T, Shimizu F, Harada O, Sugiyama A, Miyagawa S, Fukuda M, Nakayama J. Clinical utility of quantitative RT-PCR targeted to alpha1,4-N-acetylglucosaminyltransferase mRNA for detection of pancreatic cancer. Cancer Science 2006;97:119-26. [DOI: 10.1111/j.1349-7006.2006.00148.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
77 Chung KH, Ryu JK, Lee BS, Jang DK, Lee SH, Kim YT. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer. J Gastroenterol Hepatol 2016;31:506-12. [PMID: 26250642 DOI: 10.1111/jgh.13075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
78 Lévy P. Adénocarcinome du pancréas : le dosage du CA 19-9 a-t-il un intérêt ? La Presse Médicale 2008;37:88-94. [DOI: 10.1016/j.lpm.2007.05.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Usón Junior PLS, Callegaro-Filho D, Bugano DDG, Moura F, Maluf FC. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. J Gastrointest Cancer 2018;49:481-6. [PMID: 28924968 DOI: 10.1007/s12029-017-0007-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
80 Ernst B, Magnani JL. From carbohydrate leads to glycomimetic drugs. Nat Rev Drug Discov 2009;8:661-77. [PMID: 19629075 DOI: 10.1038/nrd2852] [Cited by in Crossref: 530] [Cited by in F6Publishing: 475] [Article Influence: 40.8] [Reference Citation Analysis]
81 Tsujie M, Fumita S, Wakasa T, Mizuno S, Ishikawa H, Kitani K, Satoi S, Okada K, Inoue K, Fukuda S, Manabe H, Ichimura N, Ueda S, Tamura T, Kawasaki T, Yukawa M, Ohta Y, Inoue M. A Case of Pathological Complete Response Following FOLFIRINOX Therapy for Pancreatic Adenocarcinoma with Synchronous Distant Lymph Node Metastases. Int J Surg Case Rep 2020;72:471-6. [PMID: 32698268 DOI: 10.1016/j.ijscr.2020.06.044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
82 Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1148-1154. [PMID: 18760544 DOI: 10.1016/j.ijrobp.2008.06.1483] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
83 Park JK, Paik WH, Ryu JK, Kim YT, Kim YJ, Kim J, Song BJ, Park JM, Yoon YB. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution. PLoS One. 2013;8:e78977. [PMID: 24250822 DOI: 10.1371/journal.pone.0078977] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
84 Partelli S, Frulloni L, Minniti C, Bassi C, Barugola G, D'Onofrio M, Crippa S, Falconi M. Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. Dig Liver Dis. 2012;44:945-951. [PMID: 22749648 DOI: 10.1016/j.dld.2012.05.017] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
85 Magnani JL. The discovery, biology, and drug development of sialyl Lea and sialyl Lex. Arch Biochem Biophys. 2004;426:122-131. [PMID: 15158662 DOI: 10.1016/j.abb.2004.04.008] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 5.6] [Reference Citation Analysis]
86 Maréchal R, Demols A, Gay F, de Maertelaer V, Arvanitaki M, Hendlisz A, Van Laethem JL. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas. 2008;36:e16-e21. [PMID: 18362833 DOI: 10.1097/mpa.0b013e31815f3920] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
87 Niwa T, Ueno M, Ohkawa S, Yoshida T, Doiuchi T, Ito K, Inoue T. Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy. Br J Radiol. 2009;82:28-34. [PMID: 19095814 DOI: 10.1259/bjr/43911400] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
88 Al-Shamsi HO, Alzahrani M, Wolff RA. The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. J Gastrointest Oncol 2016;7:E45-51. [PMID: 27284488 DOI: 10.21037/jgo.2016.01.05] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
89 Lim KH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. Cancer Chemother Pharmacol 2011;68:1017-26. [PMID: 21327930 DOI: 10.1007/s00280-011-1584-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
90 Park HS, Lee HS, Park JS, Park JS, Lee DK, Lee SJ, Yoon DS, Lee MG, Jeung HC. Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Res Treat 2016;48:1253-63. [PMID: 26875200 DOI: 10.4143/crt.2015.400] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
91 Lee JW, Kim YT, Lee SH, Son JH, Kang JW, Ryu JK, Jang DK, Paik WH, Lee BS. Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy. Gut Liver. 2018;12:102-110. [PMID: 29069888 DOI: 10.5009/gnl16588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
92 Quan K, Sutera P, Xu K, Bernard ME, Burton SA, Wegner RE, Zeh H, Bahary N, Stoller R, Heron DE. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma. Practical Radiation Oncology 2018;8:95-106. [DOI: 10.1016/j.prro.2017.10.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
93 Dell'Aquila E, Fulgenzi CAM, Minelli A, Citarella F, Stellato M, Pantano F, Russano M, Cursano MC, Napolitano A, Zeppola T, Vincenzi B, Tonini G, Santini D. Prognostic and predictive factors in pancreatic cancer. Oncotarget 2020;11:924-41. [PMID: 32206189 DOI: 10.18632/oncotarget.27518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
94 Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer. Oncology 2006;70:255-64. [DOI: 10.1159/000094888] [Cited by in Crossref: 100] [Cited by in F6Publishing: 102] [Article Influence: 6.3] [Reference Citation Analysis]
95 Maeda S, Motoi F, Onogawa T, Morikawa T, Shigeru O, Sakata N, Takadate T, Naitoh T, Rikiyama T, Katayose Y. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol. 2011;16:539-545. [PMID: 21455624 DOI: 10.1007/s10147-011-0220-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
96 mohamed A, Saad Y, Saleh D, Elawady R, Eletreby R, Kharalla AS, Badr E. Can Serum ICAM 1 distinguish pancreatic cancer from chronic pancreatitis? Asian Pac J Cancer Prev. 2016;17:4671-4675. [PMID: 27892682 DOI: 10.22034/apjcp.2016.17.10.4671] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
97 Vivaldi C, Caparello C, Musettini G, Pasquini G, Catanese S, Fornaro L, Lencioni M, Falcone A, Vasile E. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. Int J Cancer. 2016;139:938-945. [PMID: 27038273 DOI: 10.1002/ijc.30125] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
98 Motoi F, Rikiyama T, Katayose Y, Egawa S, Unno M. Retrospective Evaluation of the Influence of Postoperative Tumor Marker Status on Survival and Patterns of Recurrence After Surgery for Pancreatic Cancer Based on RECIST Guidelines. Ann Surg Oncol 2011;18:371-9. [DOI: 10.1245/s10434-010-1311-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
99 Boeck S, Schulz C, Stieber P, Holdenrieder S, Weckbach S, Heinemann V. Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy? Onkologie 2007;30:39-42. [PMID: 17264524 DOI: 10.1159/000097764] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
100 Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget 2017;8:97769-86. [PMID: 29228650 DOI: 10.18632/oncotarget.22080] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
101 Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012;18:530-538. [PMID: 23187839 DOI: 10.1097/ppo.0b013e31827654ea] [Cited by in Crossref: 71] [Cited by in F6Publishing: 44] [Article Influence: 7.9] [Reference Citation Analysis]
102 Lee BS, Lee SH, Son JH, Jang DK, Chung KH, Paik WH, Ryu JK, Kim YT. Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. J Gastroenterol Hepatol 2016;31:493-500. [PMID: 26220764 DOI: 10.1111/jgh.13059] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
103 Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison P, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer 2006;94:1107-15. [PMID: 16622436 DOI: 10.1038/sj.bjc.6603058] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
104 Friess H, Langrehr JM, Oettle H, Raedle J, Niedergethmann M, Dittrich C, Hossfeld DK, Stöger H, Neyns B, Herzog P. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer. 2006;6:285. [PMID: 17156477 DOI: 10.1186/1471-2407-6-285] [Cited by in Crossref: 77] [Cited by in F6Publishing: 84] [Article Influence: 4.8] [Reference Citation Analysis]
105 Batra A, Tang PA, Cheung WY. Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. Am J Clin Oncol 2021;44:519-25. [PMID: 34366400 DOI: 10.1097/COC.0000000000000856] [Reference Citation Analysis]
106 Chen S, Wang G, Niu X, Zhao J, Tan W, Wang H, Zhao L, Ge Y. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett 2014;348:20-8. [PMID: 24534203 DOI: 10.1016/j.canlet.2014.02.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
107 Kim D, Zhu H, Nassri A, Mokdad A, Kukreja S, Polanco P, Huerta S, Ramzan Z. Survival analysis of veteran patients with pancreatic cancer. J Dig Dis. 2016;17:399-407. [PMID: 27235863 DOI: 10.1111/1751-2980.12361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
108 Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer 2021;1875:188409. [PMID: 32827580 DOI: 10.1016/j.bbcan.2020.188409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
109 Gowthami J, Gururaj N, Mahalakshmi V, Sathya R, Sabarinath TR, Doss DM. Genetic predisposition and prediction protocol for epithelial neoplasms in disease-free individuals: A systematic review. J Oral Maxillofac Pathol 2020;24:293-307. [PMID: 33456239 DOI: 10.4103/jomfp.JOMFP_348_19] [Reference Citation Analysis]
110 Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, Mazza E, Zerbi A, Di Carlo V, Villa E. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009;115:2630-9. [DOI: 10.1002/cncr.24302] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 5.8] [Reference Citation Analysis]
111 Pezzilli R, Casadei R, Calculli L, Santini D, Morselli-Labate AM. Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary. Dig Liver Dis. 2010;42:73-74. [PMID: 19473891 DOI: 10.1016/j.dld.2009.04.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
112 Trifunovic J, Muzikravic L, Prvulovic M, Salma S, Nikolin B, Kukic B. Evaluation of imaging techniques and ca 19-9 in differential diagnosis of carcinoma and other focal lesions of pancreas. Arch Oncol 2004;12:104-8. [DOI: 10.2298/aoo0402104t] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
113 Goh SK, Gold G, Christophi C, Muralidharan V. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ J Surg. 2017;87:987-992. [PMID: 28803454 DOI: 10.1111/ans.14131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
114 Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9:132-138. [PMID: 18249033 DOI: 10.1016/s1470-2045(08)70001-9] [Cited by in Crossref: 154] [Cited by in F6Publishing: 75] [Article Influence: 11.0] [Reference Citation Analysis]